News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Wants More Data Before Approving Clinical Cell Culture Ltd.'s ReCell
January 16, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Australia
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
December 4, 2025
·
2 min read
·
Heather McKenzie
Vaccines
Former CDC, FDA Chiefs Decry Vaccine Policy Changes as ACIP Meeting Begins
December 4, 2025
·
2 min read
·
Dan Samorodnitsky
Policy
FDA Eyes Higher User Fees for Companies Holding Phase I Studies Abroad
December 4, 2025
·
2 min read
·
Tristan Manalac
Regulatory
COVID Contrarian Tracy Beth Høeg Named as FDA’s Acting CDER Chief
December 4, 2025
·
2 min read
·
Tristan Manalac